Mei Ri Jing Ji Xin Wen·2025-07-29 23:22Group 1 - Novo Nordisk has lowered its full-year financial guidance for 2025, expecting sales growth of 8% to 14% at constant exchange rates, down from a previous forecast of 13% to 21% [1] - The downward revision is attributed to lower growth expectations for Wegovy in the U.S. obesity market and Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration rates for Wegovy in some international markets [1] - This reflects a trend of rational return in the GLP-1 sector, indicating that even leading companies face challenges in sustaining high-speed expansion amid high bases and intense market competition [1] Group 2 - Enhua Pharmaceutical reported a net profit of approximately 700 million yuan for the first half of 2025, an increase of 11.38% year-on-year, with total revenue reaching 3.01 billion yuan, up 8.93% [2][3] - The company demonstrated steady performance in the pain relief and anesthetic sectors, maintaining a solid market position despite overall pressures in the pharmaceutical industry [2] Group 3 - Changchun High-tech's subsidiary has received FDA approval for its innovative drug, Amlodipine Besylate Oral Solution Lyophilized Powder, aimed at treating hypertension in children over 6 years old and adults with swallowing difficulties [3] - This approval enhances the company's product portfolio in the U.S. market and strengthens its competitive position in the pharmaceutical sector [3] - The product is a modified innovative drug that reduces blood pressure and minimizes the risk of cardiovascular events [3] Group 4 - Zhixiang Jintai has received clinical trial approval for its investigational product, SLEWEMI Monoclonal Antibody Injection, for passive immunity in children and adolescents exposed to suspected rabies virus [3] - This product is the world's first dual-specific antibody for rabies passive immunity, developed in accordance with WHO recommendations for antibody development [3] - The approval highlights the company's capabilities in international registration and the development of modified drugs [3]